Ambit Biosciences Corp (AMBI) 6.94 $AMBI
Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:40AM CDT
Ambit Biosciences falls 13% last trading session, continuing the downtrend
Ambit's Oncology Drug in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:55PM CDT
Ambit Biosciences commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib for acute myeloid leukemia (AML).
Ambit Announces Initiation Of Quizartinib QUANTUM-R Phase 3 Trial
PR Newswire - Tue Apr 08, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.
Ambit Announces Initiation Of Phase 2 Cohort In MD Anderson Sponsored Study Of Quizartinib In AML And High Risk MDS
PR Newswire - Mon Apr 07, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars
M2 - Thu Mar 27, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/234sqv/global) has announced the addition of the "Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars" report to their offering. Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvements in the length and quality of life and reduced disease burden for individuals and society. However, the need for innovative therapies for unmet needs /challenging diseases continues to grow, accelerating the pace of drug development directly or through partnership/ in-licensing. The authors expect innovation and improved drugs therapies through novel target discovery and technology platforms to continue to flow from the backyards of small research focused companies (Rising Stars, RS - non-profitable biotech companies) in coming years. Approval of new drugs, successful launches, maturing pipeline sustained the growth trajectory of biotech companies resulting in successful IPOs. The authors expect the optimism to percolate further into companies with novel technology platforms and targets. For more details on the trend in drug approvals, upcoming milestones and M&A in coming years please see Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars Key Topics Covered: Macro Analysis PI3K, Jak and BTK inhibitors in clinical development In-depth Company Analysis 1. Ablynx- Nanobodies - Turnarond on the Horizon 2. Ambit Biosciences- Quizartinib in RR-AML = Delayed but not Dead 3. Basilea- Drugs for Bad Bugs Isavuconazole- Watch out for ACTIVE and VITAL 4.Cempra (CEMP) 5. Endocyte 6. Enanata- The Party to Continue in 2014 - 2nd in the Oral IFN-free HCV Drug Race 7. Galapagos- Drug Discovery platform driving robust Partnership -AbbVie, GSK, Janssen,Servier. 8. Incyte - INCB39110 - Another JAK-Fruit in INCY's Bucket Leader in the Jak- 2 Inhibitor Space 9. ISIS - Beyond KYNAMRO - Targeting Other Niche Indications 10. Morphosys - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth 11. Onconova- ONTIME - Holds the Key! 12. Pharmacyclics- Ibrutinib Therapy: A Game Changer for Leukemia 13. SymBio (4582 JP) Future Growth-TREAKISYM's Label Expansion and Rigosertib's Success Industry Tables 1. Drug Clinical Milestones 2. Drug Launch Table- 2014 Companies Mentioned: - Ablynx - Ambit Bioscience - Basilea - Cempra - Enanata - Endocyte - Galapagos - Incyte - ISIS Pharma - MorphoSys - Onconova - Pharmacyclics - SymBio For more information visit http://www.researchandmarkets.com/research/234sqv/global
Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
M2 - Wed Mar 26, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6bg256/treating) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. Targeting unmet needs in the treatment of cancer through innovative drug development strategies have witnessed favourable outcomes recently. New targets have been validated in this process where kinases lead the way. The success has boosted the innovative biotech sector and is reflected in the performance of the IPOs' since 2010 till date. Positive clinical data/ regulatory approval, lucrative partnership/ acquisition announcement have increased the confidence of investors on innovation and whetted their appetite for risk associated with innovation! Several companies that have recently made their debut in public (NASDAQ) are addressing unmet needs/ niche indications with novel technology platforms/targets. Earlier, the authors had highlighted the investment opportunity and drugs being developed for Relapsed and Refractory Multiple Myeloma (RRMM). Approval of Kyprolis (carfilzomib, Onyx), Pomalyst (pomalidomide, Celgene) for this indication and their successful commercial launch validate the strategy deployed by the companies. They expect a similar scenario to unfold in the treatment of recurrent/ refractory MDS (RR-MDS, High-Risk MDS), and AML (relapsed/ refractory AML, R/R AML) and in this report highlight the new drugs and companies developing these drugs. Key Topics Covered: 1. Executive Summary 2. Investment Drivers of The Select Companies Covered 3. Myelodysplastic syndrome (MDS) 4. Acute Myelogenous Leukemia (AML) 5. Competitive Landscape: RR/ High-Risk MDS and RR AML 6. Competitive Landscape: Untreated/ Newly Diagnosed MDS and AML 7. Key Milestones 8. Launch Timeline and Commercial Opportunity of Late-stage Pipeline (RR MDS and RR AML) 9. Drivers of M&A / Licensing Deals in MDS/ AML 10.1 Ambit Biosciences (AMBI) Products Mentioned: - AC 220 - BI 6727 - C-kit positive - CPX-351 - Celgene - Elderly AML - Estybon - FLT3 mutation - IPSS-R - Quizartinib - R/R AML - Sapacitabine - Sunesis - SymBio - Vidaza - Volasertib - Vosaroxin - azacitidine - decitabine - high risk - higher risk - intermediate-1 - intermediate-2 - kinase - lower risk - lower risk - newly diagnosed - older AML - refractory - relapsed - rigosertib - stem cell transplantation For more information visit http://www.researchandmarkets.com/research/6bg256/treating
Ambit Biosciences posts lower consolidated net loss of USD11.26m in 2013
M2 - Fri Mar 21, 7:16AM CDT
Biopharmaceutical company Ambit Biosciences (NasdaqGM:AMBI) on Thursday reported a consolidated net loss of USD11.26m in 2013.
Ambit Biosciences Announces Fourth Quarter And Full-Year 2013 Operating Results
PR Newswire - Thu Mar 20, 3:10PM CDT
Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced fourth quarter and full-year operating results for 2013. The company will host a conference call today to discuss financial results for the fourth quarter and full-year 2013, and to provide an outlook on plans for 2014.
Ambit Biosciences to Announce Fourth Quarter and full-year 2013 Financial Results
PR Newswire - Thu Mar 06, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report fourth quarter and full-year 2013 operational results after closing of the NASDAQ Global Market on Thursday, March 20, 2014.
Ambit Announces Participation At Barclays Global Healthcare Conference
PR Newswire - Tue Mar 04, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014.
Ambit Announces Participation At Leerink Global Healthcare Conference
PR Newswire - Tue Feb 04, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York City, February 12-13, 2014.
Ambit Biosciences hires Mark Foletta to board
M2 - Tue Jan 28, 5:23AM CST
Biopharmaceutical company Ambit Biosciences (NasdaqGM:AMBI) reported on Monday the election of of Mark G Foletta to its board of directors, as well as chair of its audit committee.
Ambit Biosciences Appoints Mark Foletta To Board Of Directors
PR Newswire - Mon Jan 27, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the appointment of Mark G. Foletta to its Board of Directors where he will also serve as Chair of the audit committee.
Nasdaq stocks posting largest percentage decreases
AP - Fri Dec 27, 4:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
3 Stocks Under $10 Moving Higher
at The Street - Fri Dec 13, 8:30AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Ambit Biosciences Corp. (AMBI) Jumps: Stock Up 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 13, 7:39AM CST
Ambit Biosciences Corp. was a big mover last session, as its shares rose over 7% on the day.
Biotech Stock Roundup: GILD Scores FDA Approval, Ambit Plunges - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 11, 8:41AM CST
Last week's highpoint was the FDA approval of Gilead's new HCV treatment, Sovaldi.
Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
PR Newswire - Mon Dec 09, 6:00PM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55th Annual ASH Conference in New Orleans, with data highlighting the Company's lead drug candidate, quizartinib.
Strategic Collaborations, Clinical Studies, Regulatory Update, and Other Corporate Announcements - Research Report on OncoMed, Auxilium Pharma, BioTelemetry, Progenics Pharma, and Ambit Biosciences
PR Newswire - Mon Dec 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), BioTelemetry Inc (NASDAQ: BEAT), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and Ambit Biosciences Corporation (NASDAQ: AMBI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
This Week in Biotech: Part 1
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 07, 11:15AM CST
With the SPDR S&P Biotech Index up 47% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:40AM CDT
Ambit Biosciences falls 13% last trading session, continuing the downtrend
Ambit's Oncology Drug in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:55PM CDT
Ambit Biosciences commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib for acute myeloid leukemia (AML).
Ambit Announces Initiation Of Quizartinib QUANTUM-R Phase 3 Trial
PR Newswire - Tue Apr 08, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.
Ambit Announces Initiation Of Phase 2 Cohort In MD Anderson Sponsored Study Of Quizartinib In AML And High Risk MDS
PR Newswire - Mon Apr 07, 6:30AM CDT
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars
M2 - Thu Mar 27, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/234sqv/global) has announced the addition of the "Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars" report to their offering. Innovations have contributed to the availability of a range of new treatments for diseases resulting in improvements in the length and quality of life and reduced disease burden for individuals and society. However, the need for innovative therapies for unmet needs /challenging diseases continues to grow, accelerating the pace of drug development directly or through partnership/ in-licensing. The authors expect innovation and improved drugs therapies through novel target discovery and technology platforms to continue to flow from the backyards of small research focused companies (Rising Stars, RS - non-profitable biotech companies) in coming years. Approval of new drugs, successful launches, maturing pipeline sustained the growth trajectory of biotech companies resulting in successful IPOs. The authors expect the optimism to percolate further into companies with novel technology platforms and targets. For more details on the trend in drug approvals, upcoming milestones and M&A in coming years please see Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars Key Topics Covered: Macro Analysis PI3K, Jak and BTK inhibitors in clinical development In-depth Company Analysis 1. Ablynx- Nanobodies - Turnarond on the Horizon 2. Ambit Biosciences- Quizartinib in RR-AML = Delayed but not Dead 3. Basilea- Drugs for Bad Bugs Isavuconazole- Watch out for ACTIVE and VITAL 4.Cempra (CEMP) 5. Endocyte 6. Enanata- The Party to Continue in 2014 - 2nd in the Oral IFN-free HCV Drug Race 7. Galapagos- Drug Discovery platform driving robust Partnership -AbbVie, GSK, Janssen,Servier. 8. Incyte - INCB39110 - Another JAK-Fruit in INCY's Bucket Leader in the Jak- 2 Inhibitor Space 9. ISIS - Beyond KYNAMRO - Targeting Other Niche Indications 10. Morphosys - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth 11. Onconova- ONTIME - Holds the Key! 12. Pharmacyclics- Ibrutinib Therapy: A Game Changer for Leukemia 13. SymBio (4582 JP) Future Growth-TREAKISYM's Label Expansion and Rigosertib's Success Industry Tables 1. Drug Clinical Milestones 2. Drug Launch Table- 2014 Companies Mentioned: - Ablynx - Ambit Bioscience - Basilea - Cempra - Enanata - Endocyte - Galapagos - Incyte - ISIS Pharma - MorphoSys - Onconova - Pharmacyclics - SymBio For more information visit http://www.researchandmarkets.com/research/234sqv/global
Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
M2 - Wed Mar 26, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6bg256/treating) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. Targeting unmet needs in the treatment of cancer through innovative drug development strategies have witnessed favourable outcomes recently. New targets have been validated in this process where kinases lead the way. The success has boosted the innovative biotech sector and is reflected in the performance of the IPOs' since 2010 till date. Positive clinical data/ regulatory approval, lucrative partnership/ acquisition announcement have increased the confidence of investors on innovation and whetted their appetite for risk associated with innovation! Several companies that have recently made their debut in public (NASDAQ) are addressing unmet needs/ niche indications with novel technology platforms/targets. Earlier, the authors had highlighted the investment opportunity and drugs being developed for Relapsed and Refractory Multiple Myeloma (RRMM). Approval of Kyprolis (carfilzomib, Onyx), Pomalyst (pomalidomide, Celgene) for this indication and their successful commercial launch validate the strategy deployed by the companies. They expect a similar scenario to unfold in the treatment of recurrent/ refractory MDS (RR-MDS, High-Risk MDS), and AML (relapsed/ refractory AML, R/R AML) and in this report highlight the new drugs and companies developing these drugs. Key Topics Covered: 1. Executive Summary 2. Investment Drivers of The Select Companies Covered 3. Myelodysplastic syndrome (MDS) 4. Acute Myelogenous Leukemia (AML) 5. Competitive Landscape: RR/ High-Risk MDS and RR AML 6. Competitive Landscape: Untreated/ Newly Diagnosed MDS and AML 7. Key Milestones 8. Launch Timeline and Commercial Opportunity of Late-stage Pipeline (RR MDS and RR AML) 9. Drivers of M&A / Licensing Deals in MDS/ AML 10.1 Ambit Biosciences (AMBI) Products Mentioned: - AC 220 - BI 6727 - C-kit positive - CPX-351 - Celgene - Elderly AML - Estybon - FLT3 mutation - IPSS-R - Quizartinib - R/R AML - Sapacitabine - Sunesis - SymBio - Vidaza - Volasertib - Vosaroxin - azacitidine - decitabine - high risk - higher risk - intermediate-1 - intermediate-2 - kinase - lower risk - lower risk - newly diagnosed - older AML - refractory - relapsed - rigosertib - stem cell transplantation For more information visit http://www.researchandmarkets.com/research/6bg256/treating
Ambit Biosciences posts lower consolidated net loss of USD11.26m in 2013
M2 - Fri Mar 21, 7:16AM CDT
Biopharmaceutical company Ambit Biosciences (NasdaqGM:AMBI) on Thursday reported a consolidated net loss of USD11.26m in 2013.
Ambit Biosciences Announces Fourth Quarter And Full-Year 2013 Operating Results
PR Newswire - Thu Mar 20, 3:10PM CDT
Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced fourth quarter and full-year operating results for 2013. The company will host a conference call today to discuss financial results for the fourth quarter and full-year 2013, and to provide an outlook on plans for 2014.
Ambit Biosciences to Announce Fourth Quarter and full-year 2013 Financial Results
PR Newswire - Thu Mar 06, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report fourth quarter and full-year 2013 operational results after closing of the NASDAQ Global Market on Thursday, March 20, 2014.
Ambit Announces Participation At Barclays Global Healthcare Conference
PR Newswire - Tue Mar 04, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014.
Ambit Announces Participation At Leerink Global Healthcare Conference
PR Newswire - Tue Feb 04, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York City, February 12-13, 2014.
Ambit Biosciences hires Mark Foletta to board
M2 - Tue Jan 28, 5:23AM CST
Biopharmaceutical company Ambit Biosciences (NasdaqGM:AMBI) reported on Monday the election of of Mark G Foletta to its board of directors, as well as chair of its audit committee.
Ambit Biosciences Appoints Mark Foletta To Board Of Directors
PR Newswire - Mon Jan 27, 6:00AM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the appointment of Mark G. Foletta to its Board of Directors where he will also serve as Chair of the audit committee.
Nasdaq stocks posting largest percentage decreases
AP - Fri Dec 27, 4:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
3 Stocks Under $10 Moving Higher
at The Street - Fri Dec 13, 8:30AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Ambit Biosciences Corp. (AMBI) Jumps: Stock Up 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 13, 7:39AM CST
Ambit Biosciences Corp. was a big mover last session, as its shares rose over 7% on the day.
Biotech Stock Roundup: GILD Scores FDA Approval, Ambit Plunges - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 11, 8:41AM CST
Last week's highpoint was the FDA approval of Gilead's new HCV treatment, Sovaldi.
Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
PR Newswire - Mon Dec 09, 6:00PM CST
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55th Annual ASH Conference in New Orleans, with data highlighting the Company's lead drug candidate, quizartinib.
Strategic Collaborations, Clinical Studies, Regulatory Update, and Other Corporate Announcements - Research Report on OncoMed, Auxilium Pharma, BioTelemetry, Progenics Pharma, and Ambit Biosciences
PR Newswire - Mon Dec 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), BioTelemetry Inc (NASDAQ: BEAT), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and Ambit Biosciences Corporation (NASDAQ: AMBI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
This Week in Biotech: Part 1
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 07, 11:15AM CST
With the SPDR S&P Biotech Index up 47% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
